tbuckley/cabot-search huggingface dataset:
IMST-38. CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE
Authors: Carter M. Suryadevara, Pakawat Chongsathidkiet, Katherine Riccione, Patrick C. Gedeon, Rupen Desai, Bryan D. Choi, David J. Snyder, Qi-Jing Li, Peter E. Fecci, Luis Sanchez-Perez, John H. Sampson
Journal: Neuro-Oncology (2016)

Adoptive T cell immunotherapy using chimeric antigen receptors (CARs) represents a promising approach for patients with glioblastoma (GBM). CARs are synthetic transmembrane proteins that couple the antigen-binding regions of an antibody with the intracellular signaling components of a T cell receptor (TCR). CARs can be retrovirally expressed on T cells to redirect them against target antigens and induce tumor killing akin to endogenous TCR mechanisms. We developed CARs targeting the tumor-specific mutation, EGFRvIII, and found that antitumor efficacy against murine models of GBM required host preconditioning with total body irradiation prior to immunotherapy. Radiation-induced lymphopenia is believed to enhance the in vivo expansion profile and survival of T cells delivered intravenously by improving the bioavailability of homeostatic cytokines. Given the lymphodepleting effects of temozolomide (TMZ), we conducted studies to generate a clinically relevant and translatable treatment strategy for patients with GBM. Using the syngeneic GBM cell line, KR158B-Luc-EGFRvIII, we implanted tumor cells intracranially into mice and allowed tumors to engraft for 21 days to mimic disease at clinical presentation. Mouse equivalent doses of TMZ were generated based on the degree of lymphodepletion induced by standard (TMZSD) and dose-intensified (TMZDI) regimens routinely administered to patients in the clinic. CARs failed to induce antitumor responses when infused alone or following TMZSD; tumors exhibited growth kinetics similar to controls and there was no benefit in survival. In contrast, CARs administered after TMZDI induced complete regressions of these highly advanced brain tumors in >85% of mice as assessed by imaging and significantly enhanced survival. Mechanistically, TMZDI prompted a dramatic expansion of CARs and enhanced persistence in circulation and in the brain. Based on these findings, tumor-specific CARs may require TMZDI as first line chemotherapy in patients with GBM, as our results indicate that this regimen sufficiently enhances T-cell expansion and brain infiltration.
Red Blood Cell Transfusion Requirement at Diagnosis Adversely Affects Both Overall and Leukemia-Free Survival in Primary Myelofibrosis - Increased Serum Ferritin or Total Transfusion Burden Does Not
Authors: Ayalew Tefferi, Ruben A. Mesa, Jocelin Huang, Animesh D. Pardanani, Kebede Hussein, Susan Schwager, Curtis A. Hanson, David P. Steensma
Journal: Blood (2008)
Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study
Authors: Ritsuro Suzuki, Hiroshi Kimura, Yok-Lam Kwong, Yoshinobu Maeda, Chizuko Hashimoto, Won Seog Kim, Cheolwon Suh, Koji Izutsu, Fumihiro Ishida, Yoshinori Ito, Motoko Yamaguchi, Junji Suzumiya, Rie Hyo, Shigeo Nakamura, Kazuo Oshimi
Journal: Blood (2010)
In Follicular Lymphoma (FL), γδt-Lymphocytes (γδT) Are Present and Expandable from Peripheral Blood and Rare in Tumour Lymph Nodes, Mostly in Peri-Follicular Areas.
Authors: Mounia Braza, Therese Rousset, Majda Saifi, Guillaume Cartron, Sylvie Lafaye de Micheaux, Helene Sicard, Patrick Squiban, Valérie Costes, Jean-Francois Rossi
Journal: Blood (2008)
An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.
Authors: Daniel Yick Chin Heng, Toni K. Choueiri, Jae-Lyun Lee, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Ulka N. Vaishampayan, Takeshi Yuasa, Min-Han Tan, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Sumanta Kumar Pal, Christian K. Kollmannsberger, Scott A. North, Brian I. Rini, Lori Wood
Journal: Journal of Clinical Oncology (2012)

4536 Background: Clinical trials have strict eligibility criteria that exclude many patients to whom the trial results are later extrapolated to in clinical practice. Methods: mRCC patients treated with VEGF targeted therapy were retrospectively deemed ineligible for clinical trials (according to commonly used inclusion/exclusion criteria) if they had a Karnofsky Performance Status (KPS) &lt;70%, brain metastases, non-clear cell histology, hemoglobin&lt;=9 g/dL, creatinine &gt;2x the upper limit of normal, platelet count of &lt;100x10 3 /uL, neutrophil count &lt;1500/mm 3 or corrected calcium&gt;=12 mg/dL. Results: 894/2076 (43%) patients were deemed ineligible for clinical trials by the above criteria. Between ineligible versus eligible patients, the response rate, median progression free survival (PFS) and median overall survival of first-line targeted therapy were 21% vs 29%, 5.2 vs 8.8 months and 14.5 vs 28.8 months (all p&lt;0.0001), respectively. Second-line PFS (if applicable) was 3.2 months in the trial ineligible vs 4.4 months in the trial eligible patients (p=0.0074). Patients who were excluded due to KPS&lt;70, hemoglobin&lt;=9 g/dL, calcium &gt;=12, brain metastases, and non-clear cell histology, had a hazard ratio (HR) for death of 2.8 (95%CI 2.4-3.4), 1.8 (95%CI 1.4-2.2), 1.8 (95%CI 1.2-2.7), 1.4 (95%CI 1.1-1.8), and 1.4 (95%CI 1.1-1.7), respectively (all p&lt;0.01). When adjusted by the Heng et al prognostic categories, the HR for death between trial ineligible vs trial eligible patients was 1.511 (95%CI=1.335-1.710, p&lt;0.0001). Conclusions: The number of patients that are ineligible for clinical trials is high and their outcomes are inferior. Specific trials addressing the needs of protocol ineligible patients and assessing OS are required. [Table: see text]
Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)
Authors: Preetesh Jain, Keyur P. Patel, Andrew Futreal, Curtis Gumbs, Shimin Hu, Carlos Bueso Ramos, Michael Wang, Jorge Romaguera, Luis E. Fayad, Robert Z. Orlowski, Jeffrey Medeiros, Nathan Fowler
Journal: Blood (2015)
CSIG-28. NOVEL FUNCTION OF BRACHYURY AS A POTENT REGULATOR OF HEDGEHOG SIGNALING AND STEMNESS IN GLIOMA
Authors: Divya Kesanakurti, Jihong Xu, Alessandro Canella, Prerana Jha, Balveen Kaur, Vinay Puduvalli
Journal: Neuro-Oncology (2016)

Glioblastomas (GB) are the aggressive primary brain tumors with a survival of only ~1.5 years from initial diagnosis. Resistance to conventional therapies and tumor recurrence in GB has been attributed to the presence of glioma stem cells (GSCs), a subpopulation of cells which exhibit self-renewal and tumorigenesis. Brachyury, an evolutionarily conserved member of T-box family transcription factors, has been implicated in pathobiology of chordomas, lung cancer and hepatocellular carcinoma in adults; it regulates epithelial-mesenchymal transition and chemoresistance in cancer cells. However, the potential role of Brachyury in the progression of GB tumors is still unknown. We identified a significant overexpression of Brachyury protein in GSC neurospheres compared with attached glioma cell lines; conversely, serum-induced differentiation of GSCs resulted in loss of Brachyury expression accompanied by decreased levels of stemness markers. To further investigate the functional relevance of Brachyury in GSCs and glioma cells, we conducted loss-and gain-of function studies using shRNA and full-length overexpression plasmids, respectively. Brachyury knockdown in GSCs led to sphere dissociation and a significant loss of stemness markers including CD133, Nanog and Nestin; of note, Brachyury knockdown also inhibited sonic hedgehog (Shh) signaling and reduced Gli1 levels in these cells. On the other hand, overexpression of Brachyury elevated Shh/Gli1 signaling and increased stem cell marker levels in GSCs. Our ongoing studies aim to delineate the underlying transcriptional role of Brachyury in the regulation of Shh/Gli1 signaling pathway and to study its effect on in vivo tumor growth using intracranial orthotopic mice experiments. The results of our study reveal a novel role for Brachyury in the regulation of stem-like characteristics of GSCs in gliomas and examine the potential for Brachyury as a novel target for therapeutic approaches against gliomas.
The prospective study of relation between 5-HIAA/substance P and nausea/vomiting in patients receiving moderately emetogenic chemotherapy
Authors: T. Muranaka, Y. Komatsu, S. Ohnishi, K. Sawada, K. Harada, Y. Kawamoto, H. Nakatsumi, S. Yuki, M. Yagisawa, M. Nakamura, Y. Kobayashi, S. Sogabe, T. Miyagishima, N. Sakamoto
Journal: Annals of Oncology (2016)
Altered Regulation of Immune Responses in Alloimmunized Chronically Transfused Patients with Sickle Cell Disease.
Authors: Weili Bao, Susanne Heck, Wu He, Maureen Licursi, Genia Billote, Hannah Stephens, Joan Uehlinger, Margaret T. Lee, Sujit Sheth, Karina Yazdanbakhsh
Journal: Blood (2009)
Prevention of regorafenib related skin toxicity in refractory metastatic colorectal cancer (mCRC) patients (pts): a single institution experience
Authors: T. Troiani, V. Sforza, C. Cardone, A. Nappi, A. Capasso, G. Martini, S. Napolitano, N. Zanaletti, P. Vitale, P. Vitiello, F. De Vita, M. Orditura, M.L. Ferrara, F. Ciardiello, E. Martinelli
Journal: Annals of Oncology (2016)
Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.
Authors: Stefan Balabanov, Ulrike Hartmann, Winfried Kammer, Patrick Ziegler, Martin Priemer, Gerold Schwarz, Lothar Kanz, Alfred Nordheim, Tim H. Brummendorf
Journal: Blood (2004)
Co-Treatment with the hsp90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (DMAG) and Histone Deacetylase Inhibitor (HDI) Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA): A Highly Active Combination Against Human Mantle Cell Lymphoma (MCL) Cells.
Authors: Angela Hatter, Purva Bali, Maria Balasis, Warren Fiskus, Sandhya Boyapalle, Sandhya Kumaraswamy, Kathy Rocha, Michael Pranpat, Alison Hannah, Eduardo Sotomayor, Victoria Richon, Kapil Bhalla
Journal: Blood (2005)
Clinical Profile and BRAF Status of 30 Japanese Patients with Adult Langerhans Cell Histiocytosis
Authors: Miho Ogawa, Masayuki Kobayashi, Koji Jimbo, Toyotaka Kawamata, Kazuaki Yokoyama, Nobuhiro Ohno, Yoichi Imai, Satoshi Takahashi, Arinobu Tojo
Journal: Blood (2016)
Polarographic Response of Deproteinated Serum of Individual Rabbits Before and After Implantation with the Brown-Pearce Carcinoma
Authors: Benton B. Westfall, J. W. Thompson, Dean Burk, Richard Bishop, George Jarrels, Roy Moore
Journal: JNCI Journal of the National Cancer Institute (1945)

Journal Article Polarographic Response of Deproteinated Serum of Individual Rabbits Before and After Implantation with the Brown-Pearce Carcinoma Get access Benton B. Westfall, Benton B. Westfall Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Thompson, J. W. Thompson Search for other works by this author on: Oxford Academic PubMed Google Scholar Dean Burk, Dean Burk Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard Bishop, Richard Bishop Search for other works by this author on: Oxford Academic PubMed Google Scholar George Jarrels, George Jarrels Search for other works by this author on: Oxford Academic PubMed Google Scholar Roy Moore Roy Moore Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 5, Issue 6, June 1945, Pages 407–414, https://doi.org/10.1093/jnci/5.6.407 Published: 01 June 1945
Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells,
Authors: Shanshan Pei, Kevin Callahan, Mohammad Minhajuddin, Marlene Balys, Sarah Neering, Cheryl Corbett, Michael W. Becker, Jane L. Liesveld, Fred Hagen, Alan E Friedman, Peter Crooks, Craig T. Jordan
Journal: Blood (2011)
Preclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer
Authors: M.C.W. Westergaard, R. Andersen, J.W. Kjeldsen, T. Hasselager, H. Lajer, M. Donia, I.-M. Svane
Journal: Annals of Oncology (2016)
Risk factors for esophageal fistula in esophageal squamous cell carcinoma invading adjacent organs (T4b) treated with definitive chemoradiotherapy
Authors: T. Kawakami, T. Tsushima, K. Hayashi, H. Shirasu, M. Kawahira, S. Kawai, Y. Kito, Y. Yoshida, S. Hamauchi, A. Todaka, N. Machida, K. Yamazaki, T. Yokota, A. Fukutomi, Y. Onozawa, H. Yasui
Journal: Annals of Oncology (2016)
Role of solid tumor size compared with whole tumor size to predict pathologic malignant grade or prognosis in clinical stage IA lung adenocarcinoma: A multicenter study.
Authors: Y. Tsutani, Y. Ibuki, T. Ikeda, Y. Miyata, H. Nakayama, M. Okada
Journal: Journal of Clinical Oncology (2011)

7058 Background: Small lung adenocarcinoma often contains non-solid component (ground glass opacity: GGO), which is known to be low grade malignancy, on high-resolution computed tomography (HRCT). This study evaluates the usefulness of solid tumor size compared with whole tumor size on preoperative HRCT to predict pathological high-grade malignancy (positive for lymphatic invasion or vascular invasion or pleural invasion) or prognosis for clinical stage IA lung adenocarcinoma in the setting of multicenter study. Methods: We performed HRCT and fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) on 502 patients with clinical stage IA lung adenocarcinoma before they underwent curative surgical resection. Preoperative whole tumor size or solid tumor size on HRCT and surgical results were analyzed. Results: The median values of whole tumor size and solid tumor size were 2.0 cm and 1.2 cm, respectively. Receiver operating characteristics (ROC) area under the curve (AUC) values to predict pathological high-grade malignancy for whole tumor size and solid tumor size were 0.590 and 0.829 respectively. Multiple logistic regression analyses demonstrated that solid tumor size (p < 0.001) and maximum standardized uptake value (SUVmax) on FDG-PET/CT (p < 0.001) were independent variables relative to the prediction of pathological high-grade malignancy. Although three-year disease-free survival (DFS) rates were 92.5% for whole tumor size < 2.0 cm and 86.7% for whole tumor size > 2.0 cm (p = 0.51), three-year DFS rates were 92.0% for solid tumor size < 2.0 cm and 78.9% for solid tumor size > 2.0 cm (p = 0.048), and particularly, 100% for solid tumor size = 0 cm (pure GGO). Based on the multivariate Cox analyses, solid tumor size (p < 0.001) was a significantly independent factor for DFS as well as SUVmax (p = 0.05), but whole tumor size was not. Conclusions: Solid tumor size on HRCT has higher predictive values of pathological high-grade malignancy and prognosis than whole tumor size in clinical stage IA lung adenocarcinoma. Solid tumor size on HRCT should be considered to select therapeutic strategies for treating clinical stage IA lung adenocarcinoma.
Improving the efficacy of PDL1 blockade by combination with oncolytic vaccines
Authors: C. Capasso, F. Frascaro, S. Carpi, S. Feola, S. Tähtinen, M. Fusciello, S. Pesonen, T. Ranki, E. Ylösmäki, V. Cerullo
Journal: Annals of Oncology (2016)
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial
Authors: Jan Beyer-Westendorf, Sebastian M Schellong, Horst Gerlach, Eberhard Rabe, Jeffrey I Weitz, Katja Jersemann, Kurtulus Sahin, Rupert Bauersachs
Journal: The Lancet Haematology (2017)
Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis
Authors: Anna Houk, Ajay K. Gopal, Edward N. Libby, Andrei R. Shustov, Damian J. Green, Mary Philip, Johnnie J. Orozco, David G Maloney, Oliver W. Press, Stephen D. Smith
Journal: Blood (2014)
EPID-05. GLOBAL INCIDENCE OF MALIGNANT BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS
Authors: Rebecca Leece, Jordan Xu, Quinn Ostrom, Yanwen Chen, Carol Kruchko, Jill Barnholtz-Sloan
Journal: Neuro-Oncology (2016)

Incidence of malignant brain tumor varies significantly by country. The variation in incidence may point to differences in risk for brain tumor by ancestry, as well as differences in cancer registry data collection. We examined regional differences as well as differences between developed economies and developing economies. Using data from the Central Brain Tumor Registry of the United States (CBTRUS, ~99.9% of all US) and the International Agency for Research on Cancer (IARC)’s Cancer Incidence in Five Continents X, which contains data ranging from 2003-2007 from over 300 cancer registries, we calculated the average annual age-adjusted incidence rates (AAIR) per 100,000 population of brain and CNS tumors. There were significant differences in incidence of malignant brain tumors by country. Overall incidence of malignant brain tumor in the US was 7.26 in males, and 5.37 in females. Incidence was lower in Egypt (Male AAIN=4.3, Female AAIN=3.2), Brazil (Sao Paulo, Male AAIN=6.1, Female AAIN=4.6). In China, incidence was higher in females (AAIN=6.2), but lower in males (AAIN=5.4). Incidence in females was highest in Sweden (AAIN=11.0), and incidence in males was highest in Serbia (AAIN=10.5). Brain and CNS tumors are a significant source of cancer-related morbidity and mortality worldwide. Regional differences may provide clues toward genetic or environmental causes. Gaining a comprehensive understanding of the epidemiology of malignant brain tumors globally is critical to researchers, public health officials, disease interest groups and clinicians, and contributes to the direction of future research.
Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,
Authors: Jelena D. Milosevic, Filip Razga, Dana Dvorakova, Tomas Jurcek, Tiina Berg, Ana Puda, Thorsten Klampfl, Ashot Harutyunyan, Bettina Gisslinger, Heinz Gisslinger, Ester Orlandi, Paolo Bernasconi, Karel Indrak, Martina Divoka, Edgar Faber, Jiri Mayer, Zdenek Racil, Robert Kralovics
Journal: Blood (2011)
Identification of Specific Genes Expression Signatures for CEBPa, NPM1 and FLT3 Genes Mutations in AML. A Study Based of the MILE Data Issued from 79 French Samples.
Authors: Christophe Roumier, Olivier Nibourel, John Devos, Pacale Cornillet-Lefebvre, Sylvia Merk, Hervé Dombret, Norbert Ifrah, Elisabeth Macintyre, Marie-Christine Bene, Jean-Pierre Kerckaert, Torsten Haferlach, Claude Preudhomme
Journal: Blood (2007)
Stereotactic radiosurgery (SRS) for spinal tumors: The Philippine experience
Authors: J.R.M. Baclay, A.D. Gaerlan, I.M. Sih, K.J. Cortez, J.C. Rojales, M.J. Calaguas, J.M. Magsanoc, R.A.D. Torcuator
Journal: Annals of Oncology (2016)
MNGO-05. ENDOSCOPIC TRANSNASAL SUPRASELLAR APPROACH FOR ANTERIOR CLINOIDAL MENINGIOMA: CASE REPORT AND LITERATURE REVIEW
Authors: Abdulrazaq M Ajlan, Anas M Bardeesi, Saad A Alsaleh
Journal: Neuro-Oncology (2016)

Anterior clinoidal meningiomas were traditionally approached through transcranial routes. Due to their tendency to extend laterally and their close proximity to vital neurovascular structures, the endoscopic transnasal approach was still questionable. We therefore present and describe a case that underwent an endoscopic transnasal suprasellar approach, and provide a review of the literature and operative technique. A 56-year old lady was referred to us with chronic history of left sided decreased vision. MRI brain revealed a meningioma measuring 9 x 10 x 11 mm attached to the left anterior clinoid process and extending to the left optic canal. The lesion was compressing the left optic nerve and abutting the supraclinoid part of the left internal carotid artery. The decision was to proceed with resection of the meningioma because of the progressive symptoms, utilizing an endoscopic transnasal suprasellar approach. The reconstruction was achieved using fascia lata, vomer bone and nasoseptal flap. A lumbar drain was inserted perioperatively. The patient developed CSF leak postoperatively and underwent endoscopic repair of the defect with no other complications. Resection of anterior clinoidal meningiomas can be safely achieved utilizing the endoscopic transnasal approach. Although the literature lacks long term outcome comparison between the transnasal and the traditional transcranial approaches, specifically addressing anterior clinoidal meningiomas, this technique is becoming more popular over the last decade. More efforts should be directed towards implementing and reporting the endoscopic transnasal suprasellar approach for meningiomas of the anterior clinoid process.
Micro-RNA and mRNA integrative analysis revealed MMP1 as a predictor of lymph node metastasis in penile carcinomas
Authors: H. Kuasne, M.C. Barros-Filho, A. Busso-Lopes, F. Marchi, M. Pinheiro, C. Scapulatempo-Neto, J.J. Muñoz, A. Lopes, G.C. Guimarães, E.F. Faria, J.C.D.S. Trindade-Filho, S.A. Drigo, S.R. Rogatto
Journal: Annals of Oncology (2016)
Potent Anti-Cancer Activity of Anti-NTB-a Monoclonal Antibodies in Preclinical Leukemia and Lymphoma Models
Authors: Wouter Korver, Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Ishita Barman, Gerard Aguilar, Jingsong Zhao, Eric Hsi, Arie Abo
Journal: Blood (2008)
Neutrophils Clearance by Endothelial Cells Regulates Homeostasis and Coagulation.
Authors: Wen Li, Shuchuan Liu, Yueyue Fu, Jinxiao Hou, Xiushuai Dong, Rui Xie, Xue Yang, Chunyan Gao, Jin Zhou, Gary E. Gilbert, Jialan Shi
Journal: Blood (2010)
MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY
Authors: Guido Reifenberger, Martin Sill, Bettina Hentschel, Jörg Felsberg, David T. W. Jones, Dorothee Gramatzki, Kerstin Kaulich, Joerg-Christian Tonn, Ulrich Herrlinger, Gabriele Schackert, Manfred Westphal, Michael Sabel, David Capper, Rajiv Kumar, Kari Hemminki, Torsten Pietsch, Markus Loeffler, Stefan M. Pfister, Andreas von Deimling, Michael Weller
Journal: Neuro-Oncology (2016)

The median survival of patients with glioblastoma is in the range of 12-18 months in population-based studies. A minority of affected patients, however, achieve long-term survival (LTS), arbitrarily defined as survival of more than 36 months or more than 60 months after diagnosis. Prognostic factors associated with LTS include younger age, gross total tumor resection, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase (IDH) 1 or 2 mutation. LTS is exquisitely rare in elderly patients with glioblastoma. We searched the German Glioma Network (GGN) database for patients aged 71 years or more with histological confirmation of glioblastoma and survival of at least two years. Patient and tumor characteristics were retrieved from the GGN database and compared with the dataset of all patients of the same age group with confirmed death from any cause before 2 years after diagnosis. Molecular profiling included determination of MGMT promoter methylation, IDH1/2 mutation, and TERT promoter mutation status. A subset of tumors was analyzed by 450K DNA methylation profiling. Of 2071 glioblastoma patients enrolled in the GGN, 425 were aged 71 years or more; of these, 27 patients survived for 2 years or more. A comparison of these 27 patients with the 398 patients who survived shorter than 2 years revealed higher initial Karnofsky performance score, more intensive treatment up-front, and a high rate of MGMT promoter methylation as distinguishing factors. 450K profiling assigned the LTS tumors to the mesenchymal or classic subgroups that dominate in this age group. LTS in elderly patients with glioblastoma is rare. Prognostic factors for LTS resemble those in standard age patients. Host factors not captured by tumor profiling may contribute to LTS.